What question did this study set out to answer?

To identify plasma metabolomic signatures that distinguish multidrug-resistant sepsis from antibiotic-susceptible sepsis.

February 12, 2026Metabolomics0 citationsOpen Access

Plasma metabolomic signatures in patients with multidrug-resistant bacterial sepsis

JWJing WangNanjing Forestry University GLGang LuoMacao Polytechnic University PLPeng LvYuhuangding Hospital

Key Points

To identify plasma metabolomic signatures that distinguish multidrug-resistant sepsis from antibiotic-susceptible sepsis.
Metabolomic analysis of plasma samples from sepsis patients
Comparison of metabolomic profiles between MDR and antibiotic-susceptible groups
Development of a risk-stratification model for clinical application
Distinct plasma metabolomic signatures were identified for MDR and antibiotic-susceptible sepsis
Rapid metabolomics-based testing could aid in guiding antimicrobial treatment decisions
Potential improvement in clinical outcomes through early intervention

Abstract

This study identifies robust and distinct plasma metabolomic signatures that differentiate MDR from antibiotic-susceptible sepsis. These findings support the development of rapid, metabolomics-based testing using admission plasma to risk-stratify patients. This approach could guide early, stewardship-aligned antimicrobial decisions while conventional culture results are pending, potentially improving clinical outcomes.

Ask AI

Helpful

Bookmark

View Full Paper